(Q35568367)

English

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis

scientific article published on April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (English)

1 reference

Europe PubMed Central

8 August 2017

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Matthew E. Falagas

2

object named as

Matthew E Falagas

1 reference

Europe PubMed Central

8 August 2017

Konstantinos Z Vardakas

3

object named as

Konstantinos Z Vardakas

1 reference

Europe PubMed Central

8 August 2017

author name string

Xin Zhang

1

1 reference

Europe PubMed Central

8 August 2017

Rui Wang

4

1 reference

Europe PubMed Central

8 August 2017

Rong Qin

5

1 reference

Europe PubMed Central

8 August 2017

Jin Wang

6

1 reference

Europe PubMed Central

8 August 2017

Youning Liu

7

1 reference

Europe PubMed Central

8 August 2017

publication date

1 April 2015

1 reference

Europe PubMed Central

8 August 2017

Journal of thoracic disease

1 reference

Europe PubMed Central

8 August 2017

7

1 reference

Europe PubMed Central

8 August 2017

4

1 reference

Europe PubMed Central

8 August 2017

603-615

1 reference

Europe PubMed Central

8 August 2017

Tuberculosis elimination: theory and practice in Europe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Prospects for Tuberculosis Elimination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

New treatment options for multidrug-resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid in the treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid: effectiveness and safety for approved and off-label indications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Mechanism of action of the oxazolidinone antibacterial agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Linezolid for the treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Peripheral neuropathy associated with prolonged use of linezolid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Oxazolidinones: a new class of antibacterials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

12 July 2018

Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Linezolid in the treatment of MDR-TB: a retrospective clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Linezolid-associated toxic optic neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

Linezolid and reversible myelosuppression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

26 September 2018

On linezolid efficacy and tolerability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

7 December 2018

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

7 December 2018

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4419320

7 December 2018

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/25973226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicities and costs of placing prophylactic and reactive percutaneous gastrostomy tubes in patients with locally advanced head and neck cancers treated with chemoradiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25973226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25973226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

1 reference

https://pubmed.ncbi.nlm.nih.gov/25973226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China

1 reference

https://pubmed.ncbi.nlm.nih.gov/25973226

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3978/J.ISSN.2072-1439.2015.03.10

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35568367&oldid=1644988991"